
    
      This was a 2-month safety follow-up study of subjects from MannKind protocols MKC-TI-009,
      MKC-TI-102, MKC-TI-103 and MKC-TI-030. No study medications were administered during this
      trial. The adverse event data included are for the combined Safety population irrespective of
      previous treatments in the parent trials.
    
  